Literature DB >> 21821778

Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block.

Andrew C Zygmunt1, Vladislav V Nesterenko, Sridharan Rajamani, Dan Hu, Hector Barajas-Martinez, Luiz Belardinelli, Charles Antzelevitch.   

Abstract

Atrial-selective inhibition of cardiac Na(+) channel current (I(Na)) and I(Na)-dependent parameters has been shown to contribute to the safe and effective management of atrial fibrillation. The present study examined the basis for the atrial-selective actions of ranolazine. Whole cell I(Na) was recorded at 15°C in canine atrial and ventricular myocytes and in human embryonic kidney (HEK)-293 cells expressing SCN5A. Tonic block was negligible at holding potentials from -140 to -100 mV, suggesting minimal drug interactions with the closed state. Trains of 40 pulses were elicited over a range of holding potentials to determine use-dependent block. Guarded receptor formalism was used to analyze the development of block during pulse trains. Use-dependent block by ranolazine increased at more depolarized holding potentials, consistent with an interaction of the drug with either preopen or inactivated states, but was unaffected by longer pulse durations between 5 and 200 ms, suggesting a weak interaction with the inactivated state. Block was significantly increased at shorter diastolic intervals between 20 and 200 ms. Responses in atrial and ventricular myocytes and in HEK-293 cells displayed a similar pattern. Ranolazine is an open state blocker that unbinds from closed Na(+) channels unusually fast but is trapped in the inactivated state. Kinetic rates of ranolazine interactions with different states of atrial and ventricular Na(+) channels were similar. Our data suggest that the atrial selectivity of ranolazine is due to a more negative steady-state inactivation curve, less negative resting membrane potential, and shorter diastolic intervals in atrial cells compared with ventricular cells at rapid rates.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21821778      PMCID: PMC3197375          DOI: 10.1152/ajpheart.00242.2011

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  28 in total

1.  Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model.

Authors:  Vladislav V Nesterenko; Andrew C Zygmunt; Sridharan Rajamani; Luiz Belardinelli; Charles Antzelevitch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-05       Impact factor: 4.733

2.  Blockade of cardiac sodium channels by lidocaine. Single-channel analysis.

Authors:  A O Grant; M A Dietz; F R Gilliam; C F Starmer
Journal:  Circ Res       Date:  1989-11       Impact factor: 17.367

3.  Characterizing activity-dependent processes with a piecewise exponential model.

Authors:  C F Starmer
Journal:  Biometrics       Date:  1988-06       Impact factor: 2.571

4.  Post-repolarization block of cardiac sodium channels by saxitoxin.

Authors:  J C Makielski; J Satin; Z Fan
Journal:  Biophys J       Date:  1993-08       Impact factor: 4.033

5.  Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome.

Authors:  Arthur J Moss; Wojciech Zareba; Karl Q Schwarz; Spencer Rosero; Scott McNitt; Jennifer L Robinson
Journal:  J Cardiovasc Electrophysiol       Date:  2008-07-25

6.  Suppression of non-sustained ventricular tachycardia with ranolazine: a case report.

Authors:  Jeffrey W Kaliebe; David K Murdock
Journal:  WMJ       Date:  2009-10

Review 7.  Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation.

Authors:  Charles Antzelevitch; Alexander Burashnikov
Journal:  J Electrocardiol       Date:  2009-08-20       Impact factor: 1.438

8.  Intracellular calcium activates a chloride current in canine ventricular myocytes.

Authors:  A C Zygmunt
Journal:  Am J Physiol       Date:  1994-11

Review 9.  Antiarrhythmic drugs and cardiac ion channels: mechanisms of action.

Authors:  E Carmeliet; K Mubagwa
Journal:  Prog Biophys Mol Biol       Date:  1998       Impact factor: 3.667

10.  Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.

Authors:  Sandra Fredj; Kevin J Sampson; Huajun Liu; Robert S Kass
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

View more
  24 in total

1.  In silico optimization of atrial fibrillation-selective sodium channel blocker pharmacodynamics.

Authors:  Martin Aguilar-Shardonofsky; Edward J Vigmond; Stanley Nattel; Philippe Comtois
Journal:  Biophys J       Date:  2012-03-06       Impact factor: 4.033

2.  Atrial-selective sodium channel block strategy to suppress atrial fibrillation: ranolazine versus propafenone.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  J Pharmacol Exp Ther       Date:  2011-10-17       Impact factor: 4.030

3.  In silico assessment of drug safety in human heart applied to late sodium current blockers.

Authors:  Beatriz Trenor; Julio Gomis-Tena; Karen Cardona; Lucia Romero; Sridharan Rajamani; Luiz Belardinelli; Wayne R Giles; Javier Saiz
Journal:  Channels (Austin)       Date:  2013 Jul-Aug       Impact factor: 2.581

4.  Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation.

Authors:  Alexander Burashnikov; Alyssa Petroski; Dan Hu; Hector Barajas-Martinez; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2011-08-30       Impact factor: 6.343

5.  Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model.

Authors:  Vladislav V Nesterenko; Andrew C Zygmunt; Sridharan Rajamani; Luiz Belardinelli; Charles Antzelevitch
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-05       Impact factor: 4.733

6.  Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.

Authors:  Ehud Chorin; Dan Hu; Charles Antzelevitch; Aviram Hochstadt; Luiz Belardinelli; David Zeltser; Hector Barajas-Martinez; Uri Rozovski; Raphael Rosso; Arnon Adler; Jesaia Benhorin; Sami Viskin
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-10

Review 7.  Role of late sodium channel current block in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

8.  Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Dan Hu; Eyal Nof; Jonathan Blazek; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2012-06       Impact factor: 3.105

9.  Electrophysiologic characteristics and pharmacologic response of human cardiomyocytes isolated from a patient with hypertrophic cardiomyopathy.

Authors:  Hector Barajas-Martínez; Dan Hu; Robert J Goodrow; Frederic Joyce; Charles Antzelevitch
Journal:  Pacing Clin Electrophysiol       Date:  2013-10-01       Impact factor: 1.976

10.  Biophysical and molecular comparison of sodium current in cells isolated from canine atria and pulmonary vein.

Authors:  Hector Barajas-Martinez; Robert J Goodrow; Dan Hu; Payal Patel; Mayurika Desai; Brian K Panama; Jacqueline A Treat; Gary L Aistrup; Jonathan M Cordeiro
Journal:  Pflugers Arch       Date:  2017-02-27       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.